Therapeutic drug monitoring in patients with rheumatoid arthritis (RA-DRUM)

project manager

phd fellow

About the project

RA-DRUM is a clinical trial to investigate whether therapeutic drug monitoring (TDM) improves the efficacy of biologics in the treatment of arthritis. In TDM, the amount of drug in blood samples from the patient, the serum concentration, is measured and the dosage is adjusted to achieve the correct serum concentration. Part of the reason why there is a large variation in serum concentration between different patients is that the body's immune system in some patients can react to the drugs and neutralize the effect. By maintaining a high enough serum level of the drug, we believe we can counteract this process. RA-DRUM is part of the SQUEEZE project, which is a European collaboration that has received more than NOK 100 million for arthritis research from Horizon Europe, the EU's research program. 

Who can participate?

Patients over 18 years of age diagnosed with rheumatoid arthritis (arthritis) treated with biologic medications. Recruitment of participants has not yet begun.

Project arrangement

More information on the study is forthcoming.


More information about the SQUEEZE project, which RA-DRUM is part of:

This project has received funding from the European Union's Horizon Europe research and innovation program under grant agreement no. 101095052. Views and opionions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Unior nor the granting authority can be held responsible for them.


All rights reserved © REMEDY; Illustration/portrait images © Nicolas Tourrenc/Diakonhjemmet Hospital